Labels
Breast Cancers
(147)
Genitourinary Cancers
(73)
Lung Cancers
(73)
Gastrointestinal Cancers
(67)
Gynecological Cancers
(56)
Head and Neck Cancers
(50)
Cutaneous Cancers
(21)
Central Nervous System Cancers
(11)
Tuesday, 25 February 2014
Bevacizumab fails to improve overall survival in first-line treatment for glioblastoma
The February 20, 2014 issue of The New England Journal of Medicine features the results of two well-conducted, placebo-controlled, randomised trials: the Avastin in Glioblastoma (AVAglio) trial and the Radiation Therapy Oncology Group (RTOG) 0825 trial. Both studies address the clinical benefit of adding bevacizumab to the best standard treatment for newly-diagnosed glioblastoma (radiotherapy/temozolomide). Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment